Merck & Company Inc (MRK)vsVerrica Pharmaceuticals Inc (VRCA)
MRK
Merck & Company Inc
$144.85
+0.64%
HEALTHCARE · Cap: $355.10B
VRCA
Verrica Pharmaceuticals Inc
$4.91
-0.81%
HEALTHCARE · Cap: $91.05M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 219448% more annual revenue ($66.57B vs $30.32M). MRK leads profitability with a 4.8% profit margin vs -102.8%. MRK earns a higher WallStSmart Score of 36/100 (F).
MRK
Hold36
out of 100
Grade: F
VRCA
Avoid17
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$144.85
$62.01 premium
Margin of Safety
+71.5%
Fair Value
$19.54
Current Price
$4.91
$14.63 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
No standout strengths identified
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Trading at 19.6x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -111.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : VRCA
VRCA has a balanced fundamental profile.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : VRCA
The primary concerns for VRCA are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
MRK profiles as a value stock while VRCA is a turnaround play — different risk/reward profiles.
VRCA carries more volatility with a beta of 1.50 — expect wider price swings.
MRK is growing revenue faster at 5.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (36/100 vs 17/100). VRCA offers better value entry with a 71.5% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Verrica Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Verrica Pharmaceuticals Inc., a dermatological therapy company, develops and markets treatments for people with skin conditions in the United States. The company is headquartered in West Chester, Pennsylvania.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?